31
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      SlowMo, a digital therapy targeting reasoning in paranoia, versus treatment as usual in the treatment of people who fear harm from others: study protocol for a randomised controlled trial

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Paranoia is one of the most common symptoms of schizophrenia-spectrum disorders, and is associated with significant distress and disruption to the person’s life. Developing more effective and accessible psychological interventions for paranoia is a clinical priority. Our research team has approached this challenge in two main ways: firstly, by adopting an interventionist causal approach to increase effectiveness and secondly, by incorporating user-centred inclusive design methods to enhance accessibility and usability. Our resultant new digital intervention, SlowMo, intensively targets a reasoning style associated with paranoia, fast thinking, characterised by jumping to conclusions and belief inflexibility. It consists of an easy-to-use, enjoyable and memorable digital interface. An interactive web-based app facilitates delivery of face-to-face meetings which is then synchronised with an innovative mobile app for use in daily life.

          Methods/Design

          We aim to test the clinical efficacy of SlowMo over 24 weeks to determine the mechanisms through which it reduces paranoia, and to identify participant characteristics that moderate its effectiveness. In a parallel-group randomised controlled trial, with 1:1 allocation, 360 participants with distressing persecutory beliefs will be independently randomised to receive either the SlowMo intervention added to treatment as usual (TAU) or TAU, using randomly varying permuted blocks, stratified by paranoia severity and site. Research workers will be blind to therapy allocation. The primary outcome is paranoia severity over 24 weeks; our hypothesised mechanism of change is reasoning; moderators include negative symptoms and working memory; and secondary outcomes include wellbeing, quality of life, and service use. The accessibility, usability and acceptability of the digital platform will be assessed.

          Discussion

          SlowMo has been developed as the first blended digital therapy to target fears of harm from others through an inclusive design approach. In addition to testing its efficacy, this trial will add to our understanding of psychological mechanisms in paranoia. The study will examine the usability and adherence of a novel digital therapy, including an app for self-management, in a large sample of people affected by severe mental health difficulties.

          Trial registration

          ISRCTN registry, ID: ISRCTN32448671. Registered prospectively on 30 January 2017. Date assigned 2 February 2017.

          Electronic supplementary material

          The online version of this article (doi:10.1186/s13063-017-2242-7) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references69

          • Record: found
          • Abstract: found
          • Article: not found

          SPIRIT 2013 statement: defining standard protocol items for clinical trials.

          The protocol of a clinical trial serves as the foundation for study planning, conduct, reporting, and appraisal. However, trial protocols and existing protocol guidelines vary greatly in content and quality. This article describes the systematic development and scope of SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013, a guideline for the minimum content of a clinical trial protocol.The 33-item SPIRIT checklist applies to protocols for all clinical trials and focuses on content rather than format. The checklist recommends a full description of what is planned; it does not prescribe how to design or conduct a trial. By providing guidance for key content, the SPIRIT recommendations aim to facilitate the drafting of high-quality protocols. Adherence to SPIRIT would also enhance the transparency and completeness of trial protocols for the benefit of investigators, trial participants, patients, sponsors, funders, research ethics committees or institutional review boards, peer reviewers, journals, trial registries, policymakers, regulators, and other key stakeholders.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Development and validation of the penn state worry questionnaire

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The brief negative symptom scale: psychometric properties.

              The participants in the NIMH-MATRICS Consensus Development Conference on Negative Symptoms recommended that an instrument be developed that measured blunted affect, alogia, asociality, anhedonia, and avolition. The Brief Negative Symptom Scale (BNSS) is a 13-item instrument designed for clinical trials and other studies that measures these 5 domains. The interrater, test-retest, and internal consistency of the instrument were strong, with respective intraclass correlation coefficients of 0.93 for the BNSS total score and values of 0.89-0.95 for individual subscales. Comparisons with positive symptoms and other negative symptom instruments supported the discriminant and concurrent validity of the instrument.
                Bookmark

                Author and article information

                Contributors
                philippa.garety@kcl.ac.uk
                thomas.ward@kcl.ac.uk
                daniel.freeman@psych.ox.ac.uk
                D.Fowler@sussex.ac.uk
                Richard.Emsley@manchester.ac.uk
                graham.dunn@manchester.ac.uk
                elizabeth.kuipers@kcl.ac.uk
                p.bebbington@ucl.ac.uk
                Helen.Harding@slam.nhs.uk
                k.e.greenwood@sussex.ac.uk
                mar.rus-calafell@psych.ox.ac.uk
                Alison.McGourty@sussexpartnership.nhs.uk
                amy.hardy@kcl.ac.uk
                Journal
                Trials
                Trials
                Trials
                BioMed Central (London )
                1745-6215
                2 November 2017
                2 November 2017
                2017
                : 18
                : 510
                Affiliations
                [1 ]Department of Psychology, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, P077 Henry Wellcome Building, De Crespigny Park, London, SE5 8AF UK
                [2 ]ISNI 0000 0000 9439 0839, GRID grid.37640.36, South London and Maudsley NHS Foundation Trust, ; London, UK
                [3 ]ISNI 0000 0004 1936 8948, GRID grid.4991.5, Department of Psychiatry, , Oxford University, ; Oxford, UK
                [4 ]ISNI 0000 0004 1936 7590, GRID grid.12082.39, School of Psychology, University of Sussex, ; Brighton, UK
                [5 ]ISNI 0000 0004 0489 3918, GRID grid.451317.5, Sussex Partnership NHS Foundation Trust, ; Worthing, UK
                [6 ]ISNI 0000000121662407, GRID grid.5379.8, Centre for Biostatistics, School of Health Sciences, , The University of Manchester, Manchester Academic Health Science Centre, ; Manchester, UK
                [7 ]ISNI 0000000121901201, GRID grid.83440.3b, Division of Psychiatry, , University College London, ; London, UK
                [8 ]ISNI 0000 0004 0573 576X, GRID grid.451190.8, Oxford Health NHS Foundation Trust, ; Oxford, UK
                Author information
                http://orcid.org/0000-0002-7608-5755
                Article
                2242
                10.1186/s13063-017-2242-7
                5667466
                29096681
                8ec13077-7ba9-4dfd-8b62-a5c4ed838910
                © The Author(s). 2017

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 23 May 2017
                : 4 October 2017
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001922, Efficacy and Mechanism Evaluation Programme;
                Award ID: 15/48/21
                Award Recipient :
                Categories
                Study Protocol
                Custom metadata
                © The Author(s) 2017

                Medicine
                delusions,persecutory,fast and slow thinking,belief flexibility,jumping to conclusions,mhealth,ehealth,digital therapy,user-centred design

                Comments

                Comment on this article